Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02927912
Other study ID # OSU-16106
Secondary ID NCI-2016-01294
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 16, 2017
Est. completion date December 31, 2024

Study information

Verified date May 2024
Source Ohio State University Comprehensive Cancer Center
Contact The Ohio State University Comprehensive Cancer Center
Phone 800-293-5066
Email OSUCCCClinicaltrials@osumc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial studies the side effects of intraoperative electron beam radiotherapy boost and to see how well it works in treating patients with stage I-II breast cancer undergoing surgery with reconstruction. Giving a single dose of electron beam radiation to the tumor cavity during the breast surgery before reconstruction may be a better way to kill tumor cells and shrink tumors.


Description:

PRIMARY OBJECTIVES: I. To determine the rate of grade 3 breast fibrosis at 1 year in women undergoing lumpectomy with oncoplastic reconstruction and immediate intraoperative electron radiotherapy boost followed by adjuvant whole breast radiotherapy. SECONDARY OBJECTIVES: I. To determine the rate of 5 year ipsilateral breast tumor recurrence rate. II. To determine the change in self-reported cosmesis using the Breast Cancer Treatment Outcome Scale (BCTOS) questionnaire. III. To evaluate physician-reported cosmetic outcomes using the 4-point Harvard Cosmesis Scale and digital photographs. OUTLINE: Patients undergo standard of care lumpectomy and then undergo 1 fraction of intraoperative electron beam radiation therapy (IOERT) boost to the lumpectomy cavity. Patients then undergo standard of care oncoplastic reconstruction and whole breast radiation therapy. After completion of study treatment, patients are followed up at 1 month, 6 months, 1 year, and every year thereafter for 5 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 176
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pathologically proven diagnosis of breast cancer - Clinical node negative stage I (T1N0) or stage II (T2N0) breast cancer - Preoperative ultrasound of the axilla with biopsy of suspicious nodes is recommended as clinically indicated per the discretion of the treating physician - Appropriate stage for protocol entry including no clinical evidence for distant metastases based upon the following minimum diagnostic workup - History/physical examination, documentation of weight and Zubrod performance status 0-2 within 28 days prior to study entry - Right and left mammography within 90 days of diagnostic biopsy establishing diagnosis - Absolute neutrophil count > 1800 cells/cubic mm - Platelets >= 75,000 cells/cubic mm - Hemoglobin >= 8 g/dL - Women of childbearing potential must have a negative urine or serum pregnancy test within 14 days of study entry - Women of childbearing potential must be non-pregnant and non-lactating and willing to use medically acceptable form of contraception during radiation therapy - Patients must provide study specific informed consent prior to study entry Exclusion Criteria: - Clinical T4, N2 or N3, M1 pathologic stages III or IV breast cancer - Prior invasive non-breast malignancy (except non-melanoma skin cancer, carcinoma in situ of the cervix) unless disease free for a minimum of 3 yrs prior to study entry - Prior invasive or in-situ carcinoma of the breast (prior lobular breast carcinoma in situ [LCIS] is eligible) - Two or more cancers not resectable through a single lumpectomy incision - Bilateral breast cancer - Ductal breast carcinoma in situ (DCIS) only - Non-epithelial breast malignancies such as sarcoma/lymphoma - Male breast cancer - Paget's disease of the nipple - Prior radiotherapy to the breast or prior radiation to the region of the ipsilateral breast that would result in overlap of radiation fields - Pregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception - Active systemic lupus, erythematosus, or any history of scleroderma, dermatomyositis with active rash - Medical, psychiatric or other condition that would prevent the patient from receiving the protocol therapy or providing informed consent

Study Design


Intervention

Radiation:
Electron Beam Therapy
Undergo IOERT boost
Procedure:
Lumpectomy
Undergo lumpectomy
Other:
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Radiation:
Radiation Therapy
Undergo whole breast radiation therapy
Procedure:
Reconstructive Surgery
Undergo oncoplastic reconstruction

Locations

Country Name City State
Canada Centre Hospitalier de I'Universite de Montreal Québec Montreal
United States University of North Carolina Chapel Hill North Carolina
United States University Hospitals Cleveland Ohio
United States Ohio State University Comprehensive Cancer Center Columbus Ohio
United States Avera Cancer Institute Sioux Falls South Dakota

Sponsors (1)

Lead Sponsor Collaborator
Ohio State University Comprehensive Cancer Center

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events in the first 30 patients enrolled as graded by the National Cancer Institute Common Toxicity Criteria version 4.0 If 4 or more complications in the first 10 patients, 7 or more out of the first 20 patients or 9 or more out of 30 patients are observed, then the study will be deemed not safe to continue. Summary statistics will be used to report all complications. Up to 30 days after surgery and IOERT boost
Primary Rate of grade 3 fibrosis using the Late Effects Normal Tissue Task Force-Subjective, Objective, Management, Analytic scales The proportion of patients with an overall response rate of grade 3 fibrosis at 1 year from the end of therapy along with the exact binomial confidence interval for the rate will be calculated. At 1 year from the end of therapy
Secondary Change in self-reported cosmesis using the BCTOS The mean and standard deviation of the self-reported cosmesis using the BCTOS cosmesis scale will be summarized over time. The change over time using a repeated measures model or non-parametric methods, if appropriate, will be examined. Baseline up to 3 years
Secondary Physician reported cosmesis using the Harvard Breast Cosmesis scale and digital photographs physician-reported cosmetic outcomes using the 4-point Harvard Cosmesis Scale and digital photographs Up to 3 years after completion of radiation therapy
Secondary Quality of life assessed by Breast Cancer Treatment Outcome Scale determine the rate of surgical complications necessitating hospital readmission or return to the operating room within 30 days of surgery + IOERT Up to 3 years after completion of radiation therapy
Secondary Rate of ipsilateral breast tumor recurrence The exact binomial confidence interval for the rate will be calculated. At 5 years
See also
  Status Clinical Trial Phase
Completed NCT02235051 - Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors N/A
Completed NCT03233555 - Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer N/A
Terminated NCT02454777 - High-Intensity Interval Training for Stage I-III Breast Cancer Patients N/A
Completed NCT03061175 - Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy N/A
Recruiting NCT03156309 - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Phase 1
Completed NCT01928186 - FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer N/A
Terminated NCT01222377 - Endoscopic Breast Surgery in Treating Patients With Breast Cancer N/A
Active, not recruiting NCT02780401 - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Phase 1
Terminated NCT01409811 - Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid N/A
Completed NCT02728596 - S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) N/A
Completed NCT01478477 - Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole N/A
Completed NCT02314156 - Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Phase 2
Completed NCT01672684 - Phase I: At-Home Support for Rural Women Using Group Video Calling Phase 1
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00194779 - Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery Phase 2
Completed NCT02566408 - Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity N/A
Terminated NCT02370264 - Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer N/A
Terminated NCT01243541 - Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel N/A
Completed NCT01941784 - Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy N/A
Terminated NCT01712815 - PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer N/A

External Links